[Modern statin therapy in clinical practice: the lower the better]

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Context:

• Lipid and lipoprotein disorders are established risk factors for atherosclerosis and its sequelae.
• Elevated atherogenic low-density lipoprotein cholesterol (LDL-C) levels correlate directly with increased risk and progression of ischemic heart disease.
• Statin therapy is a cornerstone in managing dyslipidemias, aiming to reduce LDL-C and mitigate cardiovascular events.

Purpose:

• To emphasize the critical role of LDL-cholesterol (LDL-C) reduction in managing atherosclerosis and ischemic heart disease.
• To highlight the efficacy of statin therapy in decreasing cardiovascular mortality and morbidity.
• To underscore the challenge of achieving target LDL-C levels in a significant patient population, as indicated by studies like EUROASPIRE.

Summary:

• Epidemiological and clinical studies demonstrate that statin therapy significantly reduces cardiovascular mortality, major coronary events, and revascularization needs.
• A meta-analysis by the Cholesterol Treatment Trialists' (CTT) collaborators found a 22% reduction in cardiovascular mortality and morbidity for every 1.0 mmol/l decrease in LDL-C.
• Despite benefits, approximately 50% of patients with ischemic heart disease fail to attain recommended LDL-C targets, necessitating optimized treatment strategies.

Impact:

• Achieving target LDL-C levels, as defined by ESC/EAS guidelines (below 1.8 mmol/l or a ≥50% reduction), is crucial for high-risk patients.
• The appropriate selection of statin therapy is paramount to effectively lower atherogenic LDL-C and achieve individualized cardiovascular risk reduction goals.
• Optimizing statin therapy can improve patient outcomes and reduce the burden of cardiovascular diseases.